Evidence map›Paper›PMID 33422520›Full record

ArticleChemico-biological interactions2021

Expression of SARS-COV-2 cell receptor gene ACE2 is associated with immunosuppression and metabolic reprogramming in lung adenocarcinoma based on bioinformatics analyses of gene expression profiles.

Md Nazim Uddin, Rehana Akter, Mengyuan Li, Zeinab Abdelrahman

Open access · greenAbstract read
In one paragraph

Article in Chemico-biological interactions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. ACE2: the node connecting the lung cancer and COVID-19.American journal of cancer research · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Md Nazim UddinInstitute of Food Science and Technology, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, 1205, Bangladesh; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: nazimbio@yahoo.com.
Rehana AkterBioinformatics Research Lab, Center for Research Innovation and Development (CRID), Dhaka, Bangladesh.
Mengyuan LiSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Zeinab AbdelrahmanSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aberrant expression level of SARS-CoV-2 cell receptor gene ACE2 was reported in lung adenocarcinoma (LUAD) comorbidity of COVID-19. However, the association of ACE2 expression levels with immunosuppression and metabolic reprogramming in LUAD remains lacking. We investigated the expression level of ACE2, an association of ACE2 expression level with various types of immune signatures, immune ratios, and pathways. We employed a weighted gene co-expression network analysis (WGCNA) R package to identify the gene modules and investigated prognostic roles of hub genes in LUAD. Overexpression of ACE2 level was found in LUAD and ACE2 expression was negatively associated with various types of immune signatures including CD8

Indexed as

Adenocarcinoma of LungAmino Acid Transport System y+Angiotensin-Converting Enzyme 2ComorbidityComputational BiologyCOVID-19Databases, GeneticFemaleGene Expression Regulation, NeoplasticGlutamate-Cysteine LigaseHumansImmunity, CellularImmunity, InnateLung NeoplasmsLymphocyte ActivationMaleACE2 protein, humanAmino Acid Transport System y+Angiotensin-Converting Enzyme 2GCLC protein, humanGlutamate-Cysteine LigaseSLC7A11 protein, humanACE2Hub genesImmune-markersImmunosuppressionLung adenocarcinoma comorbidityMetabolic reprogrammingSARS-CoV-2Survival prognosis

Identifiers

PMID33422520
PMCPMC7833036
OpenAlexW3119393886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.